## LVS: Las Vegas Sands Corp. - XLY: Consumer Cyclical

### Executive Summary

No thesis match: MRS_10 -1.9% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge. Caution: momentum weakening (-4.7% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($63.15)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 8
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Retiring CEO of Las Vegas Sands Cashes in His Stock**
- Source: Barron's | 20251223T184422 | Neutral | Relevance: 100%
- Robert Goldstein, the CEO of Las Vegas Sands, has sold $167 million worth of company stock. This sale comes as the casino operator's shares have more than doubled since April, reaching a post-Covid peak, following strong performance in Macau and Singapore. Goldman Sachs recently upgraded Las Vegas Sands stock to a Buy rating.

**2. Assenagon Asset Management S.A. Has $8.58 Million Holdings in Las Vegas Sands Corp. $LVS**
- Source: MarketBeat | 20251221T080804 | Somewhat-Bullish | Relevance: 100%
- Assenagon Asset Management S.A. significantly increased its stake in Las Vegas Sands Corp. (LVS) by 1,233.9% in Q3, now holding 159,415 shares valued at $8.58 million. This increase ininstitutional investment comes despite recent large insider sales totaling over $333 million. Analysts maintain a "Moderate Buy" consensus with an average target price of $67.52, driven by positive sentiment around Macau momentum and Singapore growth.

**3. Las Vegas Sands CEO Sells Stock**
- Source: Barron's | 20251223T190811 | Somewhat-Bearish | Relevance: 98%
- Las Vegas Sands CEO Robert Goldstein sold $167 million worth of company stock this month. This sale follows a significant increase in the casino operator's share price, which has more than doubled since April, reaching a post-Covid peak. The stock surge is attributed to strong performance in Macau and Singapore, with Goldman Sachs recently upgrading Las Vegas Sands to a Buy rating.

**4. Insmed (INSM) Stock After Hours Today (Dec. 22, 2025): Closing Price, Nasdaq-100 Effect, Fresh Forecasts, and What to Watch Before Tuesdayâ€™s Open**
- Source: ts2.tech | 20251223T020902 | Somewhat-Bearish | Relevance: 63%
- Insmed (INSM) stock closed slightly higher on Monday, December 22, 2025, and traded in a tight after-hours range, influenced by its Nasdaq-100 inclusion and the continued market digestion of last week's brensocatib trial setback. Investors are weighing the impact of the Nasdaq-100 addition against the discontinuation of a key drug program. Analysts are recalibrating forecasts while maintaining a generally bullish outlook based on Insmed's broader pulmonary pipeline.

**5. Red Rock Resorts, Inc. (NASDAQ:RRR) Receives Consensus Recommendation of "Moderate Buy" from Analysts**
- Source: MarketBeat | 20251221T070941 | Neutral | Relevance: 62%
- Red Rock Resorts, Inc. (NASDAQ:RRR) has received a consensus recommendation of "Moderate Buy" from fourteen analysts, with an average 12-month target price of $64.42. The company recently reported strong quarterly earnings, beating estimates with $0.68 EPS, authorized a $300 million share repurchase, and increased its quarterly dividend to $0.26 per share. Institutional trading activity shows significant shifts in holdings, with several large investors increasing their stakes in RRR.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 3, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | Goldman Sachs | $80 | $64 | +25% |
| 2025-12-08 | UBS | $68 | $67 | +1% |
| 2025-12-01 | Argus Research | $80 | $65 | +23% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | Goldman Sachs | up | Buy |
| 2025-12-08 | UBS | main | Neutral |
| 2025-12-01 | Argus Research | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 7 ($68.68M) |
| Sells | 12 ($14.30M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 24.9% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 2 / 8 |

**Top Holders:**
- Vanguard Group Inc: 6.2% (-2.0%)
- Capital Research Glo: 5.0% (-30.9%)
- Blackrock Inc.: 4.0% (-0.1%)
- Price (T.Rowe) Assoc: 2.2% (-7.8%)
- State Street Corpora: 2.1% (-7.2%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-4.7% 5d) with bearish MACD, trend may be turning.
2. Heavy insider selling: $14M sold (12 transactions in 90 days).
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Analyst target momentum: 3 raises (avg +17%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.91 indicates undervaluation relative to growth. Forward P/E 20.8x stretched relative to 9% growth. Quality metrics strong (ROE 66%). Analyst sentiment positive (3 raises, avg +17%). Insider buying signal ($68.7M), management confidence. Institutional flow bearish (8 selling vs 2 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $45.4B |
| Beta | 0.97 |
| 52W Range | $30.18 - $70.45 |
| Short Interest | 2.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.91 |
| Forward P/E | 20.8 |
| Current P/E | 22.8 |
| YoY Growth | 9.5% |
| EPS Direction | RISING |

### Technicals

MRS_10 deteriorating from 2.9% to -1.9% (-4.7% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 4.9pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.32x) but short-term weakness (below SMA20). RSI neutral at 53. OFD pattern: -MTL (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -1.86% (CS: 32) | Neutral |
| RSI_14 | 53.1 | Neutral |
| MACD Histogram | -0.36 | Bearish |
| vs SMA20 | 0.987x | Below |
| vs SMA50 | 1.058x | Above |
| vs SMA200 | 1.324x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $66.19
- **Stop Loss:** $63.15 (4.6% risk)
- **Target:** $69.23 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 296
- **Position Value:** $19,592.24
- **Portfolio %:** 19.59%
- **Risk Dollars:** $900.00
- **Risk Per Trade:** 0.90%
- **Modifiers:** L1 120% | L2 75% | Combined 0.90x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

*NORMAL regime with moderate risk appetite in holiday-thinned conditions. VIX at 52-week lows suggests complacency, but modest breadth improvement and stable yields indicate underlying stability. Focus on quality positioning ahead of 2026 catalysts.*

### Earnings

**Next:** 2026-01-28 (Est: $0.75)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.62 | $0.78 | +25.4% |
| 2025Q2 | $0.53 | $0.79 | +48.9% |
| 2025Q1 | $0.57 | $0.59 | +3.8% |
| 2024Q4 | $0.58 | $0.54 | -6.3% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*